Adult surgery, 20% of the MCQ exam

Orthopaedics

Fractures, joint injuries, back pain and bone health. AMC tests decision rules, limb-threatening emergencies and osteoporosis.

High-yield points

  • Ottawa ankle and knee rules decide who needs an X-ray.

  • Scaphoid fracture: anatomical snuffbox tenderness after a fall on outstretched hand; immobilise even if the X-ray is normal and re-image.

  • Compartment syndrome: pain out of proportion and pain on passive stretch; urgent fasciotomy, do not wait for pulse loss.

  • Open fracture: IV antibiotics (cefazolin), tetanus cover, wound photo and cover, urgent washout.

  • Neck of femur fracture: analgesia (including nerve block), surgery within 48 hours, orthogeriatric care.

  • Cauda equina: saddle anaesthesia, bladder or bowel dysfunction, bilateral leg symptoms; urgent MRI and surgical referral.

  • Osteoporosis: DXA T-score of -2.5 or lower, or any minimal-trauma fracture; bisphosphonate or denosumab with vitamin D and calcium.

  • Paediatric limp: think transient synovitis, septic arthritis, Perthes, SUFE and non-accidental injury.

India vs Australia

Where the answer the AMC marks correct differs from what’s usually taught in Indian MBBS.

  • Bone and joint infection

    India (MBBS)

    Spinal TB (Pott's) and chronic osteomyelitis are common.

    Australia (AMC): what the exam expects

    Spinal TB is rare. Staph aureus dominates; flucloxacillin or cefazolin per eTG.

  • Imaging decisions

    India (MBBS)

    X-ray is often done routinely after injury.

    Australia (AMC): what the exam expects

    Validated rules are expected: Ottawa ankle and knee rules, Canadian C-spine rule.

  • Osteoporosis

    India (MBBS)

    Calcium and vitamin D; treatment often after fracture if affordable.

    Australia (AMC): what the exam expects

    DXA-based PBS criteria (minimal-trauma fracture or qualifying T-score). Never stop denosumab without follow-on therapy (rebound fractures).

The Australian context

Osteoporosis drugs are PBS-subsidised under specific criteria, such as a minimal-trauma fracture or a qualifying T-score by age. Stopping denosumab without follow-up therapy causes rebound vertebral fractures.